Psilocybin vs Ketamine for Alcohol Use Disorder
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.
- Status
- recruiting
- Phase
- Phase 2
- Institution
- University of Iowa
- Principal investigator
- Peggy C Nopoulos, MD
- Start date
- 2025-06-12
- End date
- 2028-04-01
- Registry ID
- NCT06405607
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.